ࡱ> Root Entry`j6@FileHeaderEDocInfo8BodyText pߜj6pߜj6 !"#$%&'Root Entryi6FileHeaderEDocInfo9BodyText i6i6   !"#$%&'()*+,-./02345678:;<=>?@ABCDFGHJKNOPQRSTUWXYZ[\]^_`abcdefghiHwpSummaryInformation.1PrvImagePrvTextDocOptions i6i6Section0VScripts i6i6JScriptVersion L DefaultJScriptI_LinkDocM X̸ 1  |: 2015D 1 29| 15:00 ~ 18:00 nj: DYP }Y 1058 \: DYP }YY : $ơ }<, \m l, DYP Y% Program 15:00 ~ 15:05 Introduction (DYP }YY,  ܭ P) 15:05 ~ 15:45 AIMP1D П<\ XՔ XȹҤ1  X̸ mմ  (DYP }YY,  ܭ P) 15:45 ~ 16:25 Human single domain antibodies and their engineered, biophysically improved versions for human immunotherapy ($ơ} <, mմt, @ ) 16:25 ~ 17:05 Protein Formulation Development ($ơ} <, 0 , \, ) 17:05 ~ 15:45 QbD and PAT for Upstream and Downstream Processing ($ơ} <, 0 , \ ) Concluding Remarks DYP }YY, ܭ P ɻGIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKٳ-@2\V[oeO޾ ;ſś8Z|Ψ8.o7ޜ2!1sfhШS^ͺװc˞MqĊznw1Ἰi rglpKw/'7}:3ϫ_\o~g^?_9TZҔu[u65wn9vS ƕe8|~]~ T=DE'(4h8pݢ 7,Bg'B6 I `{y"|l_ 1I1;,c컏? W>[.InZu- y1%Vꤌ*; QRk\R읜c 3:u%c3 4IJYE+ wfMO̝SyGκvQ.p뽰=M*Z:ҙHWP Document Fileu@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙ#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#cd߈:\Users\user-pc\AppData\Local\Temp\prv00000c10270d.gif   {`fw{@ 'NfwN{ b =  0tm2u fK KfsN0A|ڃ`PL vtB|c*&_n?~r~{f<CM;5 c/B/{k_WP^H9mlގmiL G԰Dz4&ǔ=*,l`(pִ]R5q ǴmX<"og/1_F&%OdA~jjE^*6mkoV3ֶFk=5@ɶH p\e`)+ѓ8UG*}҂ja^n$rshp#=[81p"b=:ﻬG/vn!>>p?wXf I֊ fMPJHS)OѤǙBlXү@-9l%[cu`)bI[ ݩc&ꀷ8ߥ$ԢGi5^IJ` ΀q\X-hvnU­>=f3\WC]UWt #.pѭԱpxom*(A\_F <(VЖNci0u&~0'i&γ \X=q$9-lЯx.`Ey\y!yA<\YEQe _Bʁj<ڬw(FsUjף&ʔ>ifϭ!D$N݇GBSzu1tzSpӽMk4į {aSi vr \2j=~owY΢󾜪E{i>ӿ泷Ed2&>7\-8ջmհϪUz/寳ݲQ/&ɳ~?@ABCIFGHJMNOPQRSTVWXYZ[\]^_`abcdefghHwpSummaryInformation.0PrvImagePrvTextDocOptions `j6`j6Section0UScripts `j6`j6JScriptVersion K DefaultJScriptD_LinkDocL X̸ 1  nj: DYP }Y 1058 |: 2015D 1 29| 15:00 ~18:00 \: DYP }YY : $ơ }<, \m l Program 15:00 ~ 15:05 Introduction (DYP }YY,  ܭ P) 15:05 ~ 15:45 AIMP1D П<\ XՔ XȹҤ1  X̸ mմ  (DYP }YY,  ܭ P) 15:45 ~ 16:25 Human single domain antibodies and their engineered, biophysically improved versions for human immunotherapy ($ơ} <, mմt, @ ) 16:25 ~ 17:05 Protein Formulation Development ($ơ} <, 0 , \, ) 17:05 ~ 15:45 QbD and PAT for Upstream and Downstream Processing ($ơ} <, 0 , \ ) Concluding Remarks DYP }YY, ܭ P P GIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKٳ-@2\V[oeO޾ ;ſś8Z|Ψ8.o7ޜ2!1sfhШS^ͺװc˞MqǷL3dXq%ws'VsrOw͓.n;_ӫWwܚ_|o: ߀2QWfMgev-͍_7)d>$h(,⋪qcE%hیsg8b@)Fع8ZH|C6J xړXfK5'u}؁E$헦7bSַtixTdx砄Zn~y^{lݎY'T7_u|vd:vũhbui_iȦqg&yYwM*ۛ>҈+&n:bAij6, . f)_KrTw" vR'ޅ:z[.^&k-qvGn^o 6c&YqS 1ۧoZqw塟+r ,4l|뤻lϽ FZ\;*PG]4~U٥b*ryc83jdʽf;R-t.@ʪɚt7o qEL^I/ĞZ{\ 3Q-=nY 9XuO|z%t)K. Yysqn7w]`ߠ3@/ɶ⼶t[%TY+K#*E5tFT]nODezi +(ʰPUmjC>-ӂjʰ6ˡ6x!Il/[$ `Cc~ &)cX~}>v0olBRa7}1C_S'>nQ!gy%ޭ٣4V]xUd`3$A  %VE %ɩH<{q\n0jﯽZ#^2?3@Q`=g$ 9!y('9ko>Nh0ګ5%c3HJYu@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙHWP Document File#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#cd߈:\Users\user-pc\AppData\Local\Temp\prv00000c102709.gif %  `fw:@ 'NfwNo S = 03;41( Wsm!$FJb"Q!@75$Ue,>PA0BRcA}]?B,KS Ї}C wvvLf2Ipg=;p$lPMufrxCW}ZO[+Yn)NK޹Ki@j~B0$yE+BU5쌉wg= 6}: ܙ<+zneƊNл]l=] Jc6]щ(,fs\5z+="jsРՏMZЪ$ߙZ;.{ıTRRVƚKɅv/QL(ϕ4t~hҜi :q%>' /wqn( 暤tKA:< Sg}s0D k ~G,{& ,Yl3e5Vc@J^QO9}4]Ғ^JKݬoZ-3&a8qcf }F&fҝp2Z;şI #ѱyWO]MFw2wb7ﲌE{bm,F`Jf0#gBc L ⊙ʨQ#Aio**46?PL(•7&iel=aif~Q9؏͑S(SPf1vsjc]§|ޮjƪZ0zJFt~ᥐ̍F$_o_U~|ٰv\kF, R mg+(ByYWPŒQU[ u|gY)ʱ]ƥ$y{]!۾hC>]od텇h,l=Y\.ag;i+ݸ+9Y=>l}AWCI+ޘ_ϋeg;ɋ[G8·vjY#hi [W+=yasU=YV/ K+-3FeɜJAN